How to buy Trevi Therapeutics (TRVI) stock

Trevi Therapeutics, Inc is a biotechnology business based in the US. Trevi Therapeutics shares (TRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Trevi Therapeutics employs 23 staff and has a market cap (total outstanding shares value) of 0.00.

Trevi Therapeutics stock price (NASDAQ: TRVI)

Use our graph to track the performance of TRVI stocks over time.

Trevi Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$2.05
52-week range	$1.78 - $6.73
50-day moving average	$2.13
200-day moving average	$2.53
Wall St. target price	$11.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-9.14

Buy Trevi Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Trevi Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Trevi Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trevi Therapeutics price performance over time

Historical closes compared with the close of $2.05 from 2021-05-26

1 week (2021-07-15)	N/A
1 month (2021-06-25)	-6.39%
3 months (2021-04-26)	-14.23%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Trevi Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-41.12%
Return on equity TTM	-92.66%
Profit margin	0%
Book value	$1.19
Market capitalisation	$43.8 million

TTM: trailing 12 months

Shorting Trevi Therapeutics shares

There are currently 86,330 Trevi Therapeutics shares held short by investors – that's known as Trevi Therapeutics's "short interest". This figure is 1.9% down from 87,982 last month.

There are a few different ways that this level of interest in shorting Trevi Therapeutics shares can be evaluated.

Trevi Therapeutics's "short interest ratio" (SIR)

Trevi Therapeutics's "short interest ratio" (SIR) is the quantity of Trevi Therapeutics shares currently shorted divided by the average quantity of Trevi Therapeutics shares traded daily (recently around 119902.77777778). Trevi Therapeutics's SIR currently stands at 0.72. In other words for every 100,000 Trevi Therapeutics shares traded daily on the market, roughly 720 shares are currently held short.

However Trevi Therapeutics's short interest can also be evaluated against the total number of Trevi Therapeutics shares, or, against the total number of tradable Trevi Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevi Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Trevi Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0123% of the tradable shares (for every 100,000 tradable Trevi Therapeutics shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trevi Therapeutics.

Find out more about how you can short Trevi Therapeutics stock.

Trevi Therapeutics share dividends

We're not expecting Trevi Therapeutics to pay a dividend over the next 12 months.

Trevi Therapeutics share price volatility

Over the last 12 months, Trevi Therapeutics's shares have ranged in value from as little as $1.78 up to $6.727. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevi Therapeutics's is -0.0785. This would suggest that Trevi Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Trevi Therapeutics has bucked the trend.

Trevi Therapeutics overview

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. .

Frequently asked questions

What percentage of Trevi Therapeutics is owned by insiders or institutions?
Currently 3.653% of Trevi Therapeutics shares are held by insiders and 66.281% by institutions. How many people work for Trevi Therapeutics?
Latest data suggests 23 work at Trevi Therapeutics. When does the fiscal year end for Trevi Therapeutics?
Trevi Therapeutics's fiscal year ends in December. Where is Trevi Therapeutics based?
Trevi Therapeutics's address is: 195 Church Street, New Haven, CT, United States, 06510 What is Trevi Therapeutics's ISIN number?
Trevi Therapeutics's international securities identification number is: US89532M1018